Skip to content
Featured Interview

Faye Johnson MD PhD, 2026 ENA Targets: Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy

Faye Johnson MD PhD, 2026 ENA Targets: Antibody-Drug Conjugate MICVO Targets Extracellular Matrix to Treat Metastatic Head & Neck Cancers After Platinum or Immunotherapy
The Audio Journal of Oncology

Home of the Audio Journal of Oncology

Interviews with the world's key opinion leaders in cancer

Latest Episodes

Catch up on the latest insights in oncology.

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after…

12 Nov 2026
4 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III…

2 Nov 2026
15 min
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma

Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma

MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the…

30 Oct 2026
14 min
James L Reading PhD; Nature 2026: Regulatory T-Cell Axis Identifies Pre-Malignant Lung Cancer

James L Reading PhD; Nature 2026: Regulatory T-Cell Axis Identifies Pre-Malignant Lung Cancer

LONDON, United Kingdom—Researchers in London have identified patterns of regulatory T-cells that give early warning of high risk for lung cancer. The journal Nature has just published research…

20 Oct 2026
17 min
Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse

Joseph Mikhael MD; IMS 2026: Bringing BCMA Therapies to All Patients with Multiple Myeloma at First Relapse

GLASGOW, Scotland—Joseph Mikhael MD, Professor at the Translational Genomics Research Institute (TGen), Phoenix, Arizona USA, talks with Sarah Maxwell at the International Myeloma Society 2026 Annual…

19 Oct 2026
8 min
Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This…

12 Oct 2026
9 min

Stay updated with the latest episodes

Join our newsletter to receive notifications when new oncology updates are published.